



Australian Government
Department of Health
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	324889	Eagle Cat's Claw - Echine
ARTG entry for	Medicine Listed	
Sponsor	Integria Healthcare Australia Pty Ltd	
Postal Address	PO Box 4854, EIGHT MILE PLAINS, QLD, 4113 Australia	
ARTG Start Date	15/10/2019	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Eagle Cat's Claw - Echine

Product Type	Single Medicine Product	Effective Date	22/02/2021
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Antioxidant/Reduce free radicals formed in the body

Helps reduce/decrease free radical damage to body cells

Traditionally used in South American medicine to anti-inflammatory/relieve inflammation

Anti-inflammatory/relieve inflammation

Traditionally used in South American medicine to decrease/reduce/relieve mild rheumatic aches and pains

Traditionally used in South American medicine to decrease/reduce/relieve symptoms of mild arthritis/mild osteoarthritis

Traditionally used in South American medicine to enhance/improve/promote immune defence/immunity

Traditionally used in South American medicine to helps enhance/improve/promote immune system function

Traditionally used in South American medicine to maintain/support wound healing

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.

Product presentation must only refer to mild rheumatic aches/pains.

Product presentation must not imply or refer to serious immunological diseases.

Product presentation must only refer to mild joint symptoms.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

If symptoms persist, seek the advice of a healthcare professional.

For practitioner dispensing only.

Additional Product information



Australian Government
Department of Health
Therapeutic Goods Administration

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Oral

Visual Identification

Active Ingredients

Astragalus membranaceus root Extract dry concentrate	40 mg
Equivalent: Astragalus membranaceus (Dry)	200 mg
Echinacea angustifolia root Extract dry concentrate	25 mg
Equivalent: Echinacea angustifolia (Dry)	100 mg
Echinacea purpurea root Extract dry concentrate	16.7 mg
Equivalent: Echinacea purpurea (Dry)	100 mg
Olea europaea leaf Extract dry concentrate	7.5 mg
Equivalent: Olea europaea (Dry)	75 mg
Uncaria tomentosa stem bark Extract dry concentrate	168.3 mg
Equivalent: Uncaria tomentosa (Dry)	2.02 g

Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

dextrin

hypromellose

magnesium stearate

maltodextrin

microcrystalline cellulose

silicon dioxide

sodium starch glycollate

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary